<![CDATA[Colorectal cancer is a malignancy originating from the large intestine or the last small part of the large intestine before the anus. PT Mekogene Indonesia (PT MGI) business planning focuses on the innovation of a blood test-based colorectal cancer screening tool, ColoSTAT. ColoSTAT is indicated to be able to screen the risk of colorectal cancer in adult colorectal cancer suspects aged 40-85 years. Internal analysis identified ColoSTAT's competitive advantages based on simple but highly sensitive blood test technology, with strong clinical validation. This internal analysis also identified weaknesses in the form of dependence on foreign suppliers, the need for large costs for marketing, and the need to build trust in the domestic market. In terms of financial analysis with investment feasibility projections, PT MGI showed that with an initial investment of IDR 20 billion, ColoSTAT has the potential to generate positive NPV, high IRR, and attractive ROI. The financial report also estimates that breakeven can be achieved within three years through an aggressive market expansion strategy and optimal cost management. This business plan shows that PT MGI has a planned strategy to take advantage of the great opportunities in the medical device market, especially in early detection of colorectal cancer. ColoSTAT is expected to be an effective, convenient diagnostic solution that has a big impact on improving public health in Indonesia.]]>
Copyrights © 2025
